This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suggitt, M. Articles by Bibby, M. C. Search for Related Content PubMed PubMed Citation Articles by Suggitt, M. Articles by Bibby, M. C. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches

Tom Connors Cancer Research Centre, University of Bradford, Bradford, United Kingdom

Requests for reprints: Marie Suggitt, Tom Connors Cancer Research Centre, University of Bradford, Bradford, BD7 1DP, United Kingdom. Phone: 44-1274-234271; Fax: 44-1274-233234. E-mail: m.suggitt1{at}bradford.ac.uk.

The number of anticancer agents that fail in the clinic far outweighs those considered effective, suggesting that the selection procedure for progression of molecules into the clinic requires improvement. The value of any preclinical model will ultimately depend on its ability to accurately predict clinical response. This review focuses on the major contributions of preclinical screening models to anticancer drug development over the past 50 years. Over time, a general transition has been observed from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to the target-orientated drug screening of agents with defined mechanisms of action. New approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamic and pharmacokinetic properties of compounds [e.g., the US National Cancer Institute (NCI) in vitro 60-cell line panel, hollow fiber assay, and s.c. xenograft]. Contributions of other potentially more clinically relevant in vivo tumor models including orthotopic, metastatic, and genetically engineered mouse models are also reviewed. Although this review concentrates on the preclinical screening efforts of the NCI, European efforts are not overlooked. Europe has played a key role in the development of new anticancer agents. The two largest academic drug development groups, the European Organisation for Research and Treatment of Cancer and Cancer Research UK, have been collaborating with the NCI in the acquisition and screening of compounds since the 1970s. As with the drug development process internationally, rational pharmacodynamic approaches have more recently been adopted by these two groups.

Key Words: Tumor models • pharmacodynamic

This article has been cited by other articles:

				Q. Shu, K. K. Wong, J. M. Su, A. M. Adesina, L. T. Yu, Y. T. M. Tsang, B. C. Antalffy, P. Baxter, L. Perlaky, J. Yang, et al. Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma Stem Cells, June 1, 2008; 26(6): 1414 - 1424. [Abstract] [Full Text] [PDF]

				S.-H. Kwon, J.-C. Park, S. Ramachandran, S.-D. Cha, K.-Y. Kwon, J.-K. Park, J.-W. Park, I. Bae, and C.-H. Cho Loss of Cyclin G1 Expression in Human Uterine Leiomyoma Cells Induces Apoptosis Reproductive Sciences, April 1, 2008; 15(4): 400 - 410. [Abstract] [PDF]

				F. Cano, R. Pannel, G. A. Follows, and T. H. Rabbitts Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias Mol. Cancer Ther., March 1, 2008; 7(3): 730 - 735. [Abstract] [Full Text] [PDF]

				L. Varticovski, M. G. Hollingshead, A. I. Robles, X. Wu, J. Cherry, D. J. Munroe, L. Lukes, M. R. Anver, J. P. Carter, S. D. Borgel, et al. Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models Clin. Cancer Res., April 1, 2007; 13(7): 2168 - 2177. [Abstract] [Full Text] [PDF]

				J. E. Talmadge, R. K. Singh, I. J. Fidler, and A. Raz Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer Am. J. Pathol., March 1, 2007; 170(3): 793 - 804. [Abstract] [Full Text] [PDF]

				M. Singh and L. Johnson Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin. Cancer Res., September 15, 2006; 12(18): 5312 - 5328. [Abstract] [Full Text] [PDF]

				E. A. Sausville, A. M. Burger, O. J. Becher, and E. C. Holland Contributions of human tumor xenografts to anticancer drug development. Cancer Res., April 1, 2006; 66(7): 3351 - 3354. [Abstract] [Full Text] [PDF]